Resolvin D1 (RvD1; 7S,8R,17S-trihydroxy-4Z,9E,11E,13Z,15E,19Z-docosahexaenoic acid) is an endogenous immunoresolvent that regulates acute inflammation and orchestrates resolution. Here, we investigated anti-inflammatory and proresolving actions of RvD1 after oral administration. RvD1 rapidly accumulated in the mouse plasma after oral delivery and dose-dependently (1-100 ng/mouse) reduced leukocyte infiltration in zymosan A-induced acute peritonitis. Using mathematical resolution indices, RvD1 reduced ⌿ max by ϳ50%, shortened the resolution interval by 3 h, and significantly reduced total leukocyte (by ϳ30 -45%) and polymorphonuclear neutrophil (by ϳ40 -55%) accumulation when administered at the peak of peritonitis. RvD1 also improved course and outcome of severe peritonitis, shifting it toward resolution. In peritoneal macrophages (M⌽s) from the resolution phase of peritonitis, 
Timely resolution is the ideal outcome of acute inflammation, as it is required for ensuring return to homeostasis and host health. Indeed, when unresolved, inflammation can become chronic, cause further damage, and contribute to the pathogenesis of many highly burdening diseases (1) (2) (3) . Several endogenous chemical mediators orchestrate the resolution of inflammation (3) . For instance, annexin A1 (AnxA1) is a glucocorticoidinduced protein that regulates leukocyte trafficking, reduces proinflammatory molecules, and restores tissue integrity (4) . Furthermore, the polyunsaturated fatty acids (PUFAs) arachidonic acid (AA; 5Z,8Z,11Z,14Z-eicosatetraenoic acid), 5Z,8Z,11Z,14Z,17Z-eicosapentaenoic acid (EPA), and 4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoic acid (DHA) are bioprecursors of specialized proresolving lipid mediators (SPMs) that play pivotal roles in endogenous anti-inflammatory and resolution programs (5) . Among them, lipoxins (LXs) represent the prototype of SPM biosynthesized from AA during a lipid mediator (LM) class switching, characteristic of self-contained acute inflammatory reactions (6, 7) , as they carry potent immunoresolvent actions when administered therapeutically in experimental diseases (reviewed in ref. 8) . Recently, a new set of SPMs derived from DHA has been identified with targeted LM metabolomics (9) , providing new mechanisms for the beneficial actions of PUFAs. The recognition of resolution as a programmed process governed by specific chemical mediators provides previously unforeseen opportunities in human pharmacology, namely harnessing endogenous controllers of inflammation as therapeutics or biotemplates for drug development (10, 11) . For example, AnxA1 served as model for the generation of peptides (12, 13) and nanoparticles (14) that dampen inflammation and protect from tissue damage. Likewise, several LX-stable analogs obtained by organic synthesis proved to have anti-inflammatory and organprotective activities (15) (16) (17) and, along these lines, Norling et al. (18) recently demonstrated the efficacy of human neutrophil-derived nanoparticles carrying a benzo-LX analog in reducing peritoneal and joint inflammation. Hence, the exploration of pharmacological properties of SPM is of considerable interest since many human chronic inflammatory diseases have defective proresolution mediators and mechanisms (19 -22) .
Resolvin D1 (RvD1; 7S,8R,17S-trihydroxy-4Z,9E,11E, 13Z,15E,19Z-docosahexaenoic acid; ref. 23 ) is a DHAderived SPM formed by lipoxygenases during resolution (23, 24) . In humans, leukocytes contribute to the biosynthesis of RvD1 (23) , which can be detected in plasma and serum (25, 26) . Consistent with shared immunoresolvent actions of SPM, RvD1 limits polymorphonuclear neutrophil (PMN) infiltration in inflamed tissues, enhances nonphlogistic phagocytosis (i.e., efferocytosis) by macrophages (M⌽s), and promotes tissue repair (see ref. 5 for a recent review). RvD1 also favors resolution of allergic airway inflammation (27) , reduces inflammation in the adipose tissue (28, 29) , and accelerates the healing of diabetic wounds (10) . The immunoresolving actions of RvD1 involve regulatory mechanisms on transcription factors, microRNAs, and select genes (30) and are mediated by two specific receptors, LXA4 (5S,6R,15S-trihydroxy-7E,9E,11Z,13E-eicosatetraenoic acid) receptor/formyl peptide receptor 2 (ALX/FPR2) and G-protein coupled receptor 32/RvD1 receptor 1 (GPR32/DRV1) (31, 32) , as confirmed by several studies with genetically engineered mice, selective receptor antagonists, or blocking antibodies (Abs) (10, 28, 30 -38) .
M⌽s are crucial for innate immunity, resolution of inflammation, and homeostasis, being endowed with exquisite defensive, tissue remodeling, and housekeeping functions (39) . These multiple tasks are accomplished through the acquisition of selective gene expression patterns linked either to proinflammation or proresolution (40) . For example, the "classically activated" M1 M⌽s, which are mainly responsible for perpetuation of inflammation, express high levels of cytokines, chemokines, and adhesion molecules (41) . Conversely, the "alternative" M2 phenotype is associated with high expression of anti-inflammatory/immune-suppressant IL-10 and tumor growth factor-␤ (41). Furthermore, M⌽s acquire a distinct "proresolving" phenotype during the resolution of inflammation, bearing proteins related to antigen presentation, regulation of leukocyte trafficking, and biosynthesis of SPMs (42) (43) (44) . Interestingly, the transcriptional and functional heterogeneity of M⌽ subsets is mirrored by their LM biosynthetic signature. Indeed, while M1 M⌽s mainly produce the proinflammatory leukotriene B 4 and prostaglandins (PGs), the M2 subtype biosynthesizes more SPMs that temper inflammation and enhance proresolving and protective actions of M⌽s (43, 45) . Several chromatin remodeling enzymes (e.g., histone methylases, demethylases, acetyltransferases, deacetylases, and kinases) dictate the transcriptional output of M⌽s and, ultimately, their responses and functions in inflammatory/resolving milieus by regulating the permissiveness to RNA polymerase through covalent modification of DNA bases or histone proteins (40) . Since RvD1 skews transcriptional profiles in M⌽s linked to anti-inflammation and proresolution (28, 29, 46) , whether it acts on regulatory mechanisms of mRNA transcription in M⌽s to drive their proresolving functions and orchestrate resolution is of interest.
Here, we demonstrate that orally administered RvD1 regulates inflammation resolution programs. Moreover, it initiates a selective regulation of the transcriptomic profile of M⌽s, by regulating specific chromatin-remodeling enzymes, which enhances phagocytic activity of M⌽s during the resolution of inflammation.
MATERIALS AND METHODS

Materials
RvD1 and enzyme immunoassay (EIA) kits were purchased from Cayman Chemical (Ann Arbor, MI, USA). Before each experiment, concentration and integrity of RvD1 were assessed with UV spectroscopy ( max at 301 nm in methanol (see ref. 23) , and the compound was dissolved in the appropriate vehicle and kept in the dark on ice. All the Abs used for differential analysis of leukocytes were from BioLegend (San Diego, CA, USA), and the anti-coactivator-associated arginine methyltransferase 1 (CARM1) Ab was obtained from Cell Signaling (Billerica, MA, USA). Tumor necrosis factor ␣ (TNF-␣) and keratinocyte-derived chemokine (KC) ELISA kits were purchased from Peprotech (London, UK) and eBioscience (San Diego, CA, USA). Other chemicals were obtained from Sigma-Aldrich (Milan, Italy).
Murine peritonitis and flow cytometry (FCM)
In vivo studies were approved by the local Ethics Committee for the Use of Animals at the G. d'Annunzio University (protocol 44/2011/CEISA/PROG/26). C57BL/6N mice (males, 6 -8 wk old, Charles River, Calco, Italy) were maintained on a 12-h dark-light cycle and given food (Altromin M; Rieper, Bolzano, Italy) and water ad libitum. Fat composition of diet included 7.5 g/kg -6 linoleic acid and 1.2 g/kg (as a mixture of 18:3, 18:4, 20:5, and 22:6 fatty acids). Peritonitis was initiated via intraperitoneal (i.p.) injection of zymosan A (1 mg in 1 ml of sterile saline). RvD1 (1-100 ng/mouse corresponding to ϳ0.5-5 g/kg) or vehicle (0.5% v/v ethanol) was delivered through oral gavage of 0.2 ml of saline using a sterile blunt-end needle inserted directly into the gastric cavity (47) . In some experiments, peritonitis was induced with 10 mg zymosan (i.p. injection). Peritoneal leukocytes were collected, stained with Turk's solution to exclude erythrocytes, and counted. For multicolor FCM analysis, cells were incubated (15 min, 4°C) in MACS buffer (Miltenyi Biotec, Auburn, CA, USA) with the Abs listed in Supplemental Table S1 and analyzed on a fluorescenceactivated cell sorting (FACS) Canto II analyzer equipped with the FACS Diva software (both from BD Biosciences, San Jose, CA, USA). All Abs were titrated under assay conditions, and optimal photomultiplier voltages were established for each channel using calibration beads (BD Biosciences). Each leukocyte population was identified on the basis of antigen expression, as well as size and granularity on forward-scatter/sidescatter (FSC/SSC) plots as follows high , CD11b Ϫ . Differential cell numbers were used to determine resolution indices as in Bannenberg et al. (7) . Analysis of efferocytosis in resolving peritonitis was carried out as in Schif-Zuck et al. (43) .
Determination of RvD1 plasma levels with EIA
Mouse plasma (ϳ100 l) obtained on centrifugation (1000 g, 4°C) of blood withdrawn through intracardiac puncture was mixed with 9 vol of sodium acetate (0.1 M, pHϭ5.0) and taken to solid-phase extraction (SPE; C-18 columns, Bond Elut Varian; Agilent Technologies, Milan, Italy). Samples were eluted with methanol, taken to dryness, and suspended in 100 l of EIA buffer. For RvD1 measurements, 50 l of sample (further diluted 1:10 with EIA buffer) were used following the manufacturer's protocol. PGB 2 (5 ng/sample; Cayman Chemical) was added to samples prior to extraction and used to calculate extraction recoveries with reversedphase high-performance liquid chromatography (RP-HPLC) using an Agilent 1100 system with a Hypersil C-18 column (300 ϫ 4 mm ϫ 5 m; Waters, Milford, MA, USA). Mobile phase consisted of methanol:water:acetic acid (65:35:0.01% vol/vol). PGB 2 was identified on the basis of coelution with authentic standard, retention time, and UV spectrum characteristics.
Sorting of resolution-phase M⌽s
Peritoneal leukocytes (ϳ10 7 ) were collected at 24 h of peritonitis and were immediately fixed with 3% formalin to prevent cell activation and death. Then, they were stained with CD11b, Gr-1, F4/80, CD45, and Ter-119 Abs, as described above. M⌽s were isolated using a FACS Aria III cell sorter (BD Biosciences). Cell aggregates were identified using a sequential gating strategy based on FSC area/width followed by SSC area/width pulse comparisons and removed from analysis. Postsorting analyses were carried out to assess M⌽ purity, and only those preparations with purity Ն 95% were used for molecular analyses. Sorted cells were suspended with RNA isolation buffer (Norgen Biotek, Thorold, ON, Canada) and snap-frozen at Ϫ80°C.
Gene expression analyses
Lysed pellets from sorted M⌽s were incubated overnight at 55°C with sodium dodecyl sulfate and proteinase K (Roche, Basel, Switzerland) to remove DNA-protein cross-links, total RNA was extracted, and cDNA was synthesized with the Omniscript system (Qiagen). Expression profile of chromatin remodeling enzymes was assessed with a real-time PCR array (RT 2 Profiler PCR Array PAMM-085Z; SA Bioscience; Qiagen, Milan, Italy) using QuantiTech SYBRGreen master mix (Qiagen). Results were analyzed using the 2
Ϫ⌬Ct relative expression method. Clustering and heat map generation were carried out with Cluster 3.0 and TreeView software (http://bonsai.hgc.jp/ mdehoon/software/cluster/). Quantitative PCR (qPCR) on individual genes was carried out using specific primers (Eurofins MWG Operon, Ebersberg, Germany) and SYBRGreen master mix (5Prime; Eppendorf, Milan, Italy). Gene networks and functional associations were generated with the Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, Redwood, CA, USA; http://www.ingenuity.com).
M⌽ transfections, in vivo adoptive transfer, gene expression, and phagocytosis analysis
Human M⌽s (hM⌽s), differentiated from peripheral blood monocytes as previously reported (30, 31) , and murine RAW 264.7 cells were transfected with CARM1-or nontargeting (NT) siRNAs (20 nM, Flexitube; Qiagen) using the interferin reagent (0.3 l/nmol of siRNA; Polyplus, Illkirch, France). After 72 h, expression levels of CARM1 in siNT or siCARM1-transfected cells were determined with qPCR and FCM. For adoptive transfer, hM⌽s were injected (7.5ϫ10 4 /mouse, i.p. injections) to mice 6 h after zymosan administration. Infiltrated PMN in peritoneal lavages were determined 6 h after the transfer as described above. For evaluation of CARM1-dependent genes, siNT or siCARM1 RAW 264.7 cells were treated in serum-free medium with LPS (10 g/ml) 72 h post-transfection. After 6 h, total RNA was collected and used for real-time PCR. Phagocytosis of FITC-zymosan was measured as previously reported (31) using a Spectramax Gemini II fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA).
Statistical analysis
Results are expressed as arithmetic means Ϯ se, unless otherwise indicated. Statistical analysis was performed with the Sigma Plot 11 software (Systat Software, San Jose, CA, USA) using 1-way ANOVA followed by Holm-Sidak or Dunn's post hoc test, with values of P Ͻ 0.05 considered to be significant. assess RvD1 absorption after oral administration. To this end, RvD1 (100 ng/mouse) was delivered directly into the mouse stomach by gavage, a route that closely mimics delivery of drugs in clinical treatments. Next, we measured RvD1 plasma concentrations after enteric delivery. Owing to possible interference of plasma proteins and lipids with enzyme-based detection of eicosanoids (48), we validated the EIA system and assessed the linearity of its detection range by spiking mouse plasma with authentic RvD1 (0.015-0.250 ng/ ml) and measuring its levels after SPE. As shown in Fig. 1A , RvD1 levels after SPE in samples correlated (r 2 ϭ0.982, PϽ0.001) with the amounts added to plasma. With the validated extraction and quantification method, we found that basal plasma concentrations of RvD1 were ϳ0.2 ng/ml, increased up to ϳ0.8 ng/ml at 3 h after gavage, and returned to baseline by 24 h (Fig.  1B) . Subsequently, we determined primary and secondary pharmacokinetics (PK) parameters. The area under the curve (AUC 0-last ), i.e., a measure of total body exposure to RvD1, was ϳ4.5 ng/h/ml, while the apparent clearance (CL=), which reflects the volume of blood cleared from RvD1 in the time unit, was 22.03 ml/h, and the volume of distribution (V d ), an index of RvD1 distribution in the body, was ϳ4.8 ml (Fig. 1B) . Moreover, since the elimination of RvD1 from plasma followed a first-order kinetic (Fig. 1B , inset), we estimated the first-order elimination rate constant (K el , 0.231 h Ϫ1 ) and half-life (T 1/2 , ϳ3 h). These results indicate rapid absorption of RvD1 from the gastrointestinal cavity on delivery, passage into the bloodstream, and elimination from the vascular compartment (49) .
Orally administered RvD1 regulates acute inflammation and expedites the onset of resolution
Having established PK of RvD1 after oral delivery, we investigated its anti-inflammatory actions in murine zymosan A-induced acute peritonitis. To this end, RvD1 was given by gavage 15 min beforer i.p. injection of zymosan in order to allow absorption and distribution into peripheral blood. RvD1 (1-100 ng/mouse) significantly dampened total leukocyte (40 -62%) and PMN (50 -66%) recruitment at 3 h in a dose-dependent manner ( Fig. 2A, B) and significantly reduced levels of the major proinflammatory mediators TNF-␣ and KC (CXCL1) in exudates by ϳ30% and ϳ50% ( Table 1 ) at 6 h and declining by 24 h (5.88Ϯ 0.59ϫ10 6 ) (Fig. 2D ). Oral RvD1, as low as 100 ng/ mouse, significantly reduced (ϳ30 -60%) the number of infiltrating leukocytes at 3, 6, 12, and 24 h after zymosan injection ( (T max ), consistent with their pivotal role in early phases of acute inflammatory responses. PMN number decreased by 50% at ϳ10 h (T 50 ), giving a resolution interval (R i ϭ T 50 Ϫ T max ) of ϳ4 h for the natural, spontaneous resolution process (Fig. 2E) . Oral administration of RvD1 sharply reduced the ⌿ max (8.90Ϯ3.41ϫ10 6 ; Fig. 2E and Table 2 ). Next, we evaluated time required for reaching the ⌿ 50 of natural resolution and found a left-shift of ϳ3 h in RvD1-treated compared to vehicletreated mice. We also determined selective actions of RvD1 on different leukocyte types. RvD1 selectively diminished monocytes and M⌽s at 12 h after zymosan injection, lymphocytes at 6 h, and eosinophils at 3 h peritonitis (Fig. 2F) . To evaluate therapeutic efficacy of RvD1 in reducing acute inflammation, mice were challenged with zymosan and administered oral RvD1 (100 ng/mouse) or vehicle 6 h later (i.e., at the peak of peritonitis). Inflammatory exudates were collected and analyzed 6 and 18 h after drug administration (12 and 24 h from inflammatory insult). As shown in (Fig. 3B) , suggesting that RvD1 has selective actions on the recruitment mechanisms of leukocytes, namely stopping neutrophils and enhancing monocyte-M⌽ accumulation. We also sought to test oral RvD1 actions in delayed-resolution peritonitis that resembles aggressive and prolonged inflammation often seen in patients (50) . To this end, mice were challenged with higher (10 mg/mouse, i.p. injection) doses of zymosan and monitored up to 48 h for clinical signs of diseases and leukocyte infiltration. As shown in Fig. 3C , mice administered higher dosage of zymosan developed a severe peritonitis characterized by rapid loss of up to ϳ10% of initial body weight during the first 24 h, 30% lethality, and an exacerbated PMN accumulation that was significantly higher at 24 h compared to that evoked by 1 mg zymosan (9.24Ϯ0.5ϫ10 6 vs. 2.49Ϯ0.5ϫ10 6 , P Ͻ 0.001) and remained sustained at 48 h (10.79Ϯ1.36ϫ10 6 ). Oral delivery of RvD1 (100 ng) 24 h after initiation of peritonitis gave a significant reduction of mortality (Fig. 3C ) and decreased numbers of infiltrated PMNs (ϳ70%) at 48 h, initiating resolution as early as 17 h from its administration. Together, these results demonstrate that oral RvD1 reduces early and late phases of acute inflammation, shortens the time required for initiating resolution, and reverts the outcome of severe, delayed-resolution inflammation. (Fig. 4A) . Postsorting analysis confirmed that cell preparations were Ն95% M⌽s, and therefore suitable for qPCR (Fig. 4B) . We therefore evaluated the expression levels of select enzymes (e.g., DNA methylases, histone acetylases, deacetylases, methyl transferases, and protein kinases) that regulate chromatin organization. Real-time PCR analysis followed by hierarchical clustering based on fold change in expression induced by RvD1 showed 4 clusters (Fig.  4C) . In particular, CARM1, histone aminotransferase 1 (HAT1), histone deacetylase 5 and 7 (HDAC5 and HDAC7), protein arginine N-methyltransferase 2 (PMRT2), and ribosomal protein S6 kinase, polypeptide 5 (RPS6KA5) were significantly down-regulated (ϳ2-to 3-fold) by RvD1 (Fig. 4D) . To identify biological pathways influenced by RvD1-regulated enzymes and downstream genes, we used bioinformatics coupled to targeted transcriptomics. Computational analysis with IPA identified 17 biological functions associated with RvD1-regulated enzymes, mainly related to immunity (e.g., humoral and cell-mediated immune response, immune cell trafficking, hematological system development and function), cell physiology (e.g., cellular compromise, cell cycle, cell growth, and proliferation), and cell responses to stimuli (lipid metabolism, cell signaling, cell-cell signaling, and interaction) (Fig. 5A and Supplemental Table S2 ). Also, CARM1, HAT1, PMRT2, RPS6K, HDAC5, and HDAC7 were linked either directly or indirectly by physical or functional connections (Fig. 5B) , indicating cooperative mechanisms in the regulation of the mRNA transcription machinery. In particular, CARM1 occupied a central position in the IPA network and was directly associated with proinflammatory genes, such as colony stimulating factor 3 (CSF3), intercellular adhesion molecule 1 (ICAM-1), and chemokine (C-X-C motif) ligand 2 (CXCL2), also called monocyte inflammatory protein 2 (MIP-2). Functional analysis revealed that these genes have important functions in promoting PMN recruitment, transmigration, and activation in inflammatory loci. Also, they are abundantly expressed by M1 M⌽s compared to M2 and decrease M⌽ phagocytosis, a pivotal M⌽ task in resolution of inflammation (Supplemental Table S2 ). In order to determine whether RvD1-induced CARM1 reduction regulated inflammation and resolution, we carried out knock-down experiments. As shown in Fig. 6A , siRNA-mediated silencing reduced CARM1 mRNA and protein both in mouse RAW 264.7 cells and primary human M⌽s. Further, knockdown of CARM1 gave reduced expression of CARM1-downstream genes ICAM-1 and MIP-2 in response to proinflammatory stimuli (Fig. 6B) . These results are consistent with previous studies with Carm1-deficient mice (52) and demonstrate that this enzyme is crucial for the regulation of transcription of inflammation-related genes. Consistent with this, M⌽s sorted from RvD1-treated mice had significantly lower mRNA levels of ICAM-1, and MIP-2 and reduced surface expression of ICAM-1 (Fig. 6C) . Notably, cyclooxygenase 2 (COX-2) and nuclear factor of light polypeptide gene enhancer in B cells inhibitor (IB), which were not connected to CARM1 (Fig. 5B) , were not regulated by RvD1 (Fig.  6A) , indicating that RvD1 down-regulation of CARM1-linked genes is specific and not due to global suppression of mRNA synthesis. Moreover, in order to translate transcriptomics into functions and to underscore roles of CARM1 in human M⌽s, since CARM1 downstream genes have roles in phagocytosis (Supplemental Table  S2 ), we investigated whether its knockdown regulates this key proresolution activity. As shown in Fig. 6E , CARM1-knockdown M⌽s phagocytosed a significantly higher amount of zymosan. More strikingly, adoptive transfer of siCARM1-transfected hM⌽s to zymosanchallenged mice resulted in a significant increase in PMN clearance (K 50 2.25Ϯ0.02ϫ10 6 vs. 1.64Ϯ0.02ϫ10 6 PMN/h, PϽ0.001) and reduction (ϳ70%, PϽ0.001) in PMN infiltration compared to siNT-transected M⌽s (Fig. 6E) , mimicking RvD1 actions (Fig. 3A) . Finally, consistent with this, orally administered RvD1 signifi- 
RvD1 regulates the transcriptional profile of resolution-phase M⌽s
Having established that orally administered RvD1 exerts potent anti-inflammatory and proresolution actions and since RvD1 regulates gene expression in M⌽s (28, 29, 46), we examined whether it acted on epigenetic mechanisms that control the transcription of genes in M⌽s, since they have crucial roles in regulating their tasks during inflammation and resolution (51). To this end, M⌽s were sorted from mice treated with vehicle or RvD1 (6 h after injection of zymosan) at 24 h of peritonitis.
DISCUSSION
Here, we demonstrate immunoresolving actions of RvD1 exerted after oral administration. Oral delivery to mice elevated RvD1 in plasma, reduced acute inflammation when administered either at the beginning or at the peak of peritonitis, and accelerated or initiated resolution. RvD1 also down-regulated select enzymes controlling the transcription of inflammation-related phagocytosis genes in M⌽s. These findings uncover biological properties and modes of action of RvD1 in resolution circuits.
Given the pathogenetic role of unresolved inflammation in several human diseases and the many side effects of current anti-inflammatory drugs (2, 4, 11) , the pharmacological exploration of endogenous mediators as novel therapeutics for curtailing acute inflammation and promoting its resolution is of paramount interest. In the present report, using a preclinical C) Heat map cluster shows fold up-regulation or down-regulation of ϳ90 genes related to chromatin structure from resolution-phase M⌽s sorted from mice treated with zymosan ϩ oral RvD1 (100 ng/mouse, given 6 h after injection of zymosan), compared to the zymosan ϩ vehicle-treated group at 24 h of peritonitis onset (see Materials and Methods). Results from qPCR were analyzed using the 2 Ϫ⌬Ct method with GAPDH (NM_008084), GUSB (NM_010368), and HSP90AB1 (NM_008302) chosen as housekeeping reference genes. Genes were grouped on the basis of fold changes induced by RvD1, indicated in a green-red color code. D) Genes significantly down-regulated in RvD1-treated mice. Dotted lines indicate the P ϭ 0.05 value used as cutoff for significance. CARM1, coactivator-associated arginine methyltransferase; HAT1, histone aminotransferase 1; HDAC5, histone deacetylase 5; HDAC7, histone deacetylase 7; PRMT2, protein arginine N-methyltransferase 2; RPS6KA5, ribosomal protein S6 kinase, polypeptide 5.
model of peritoneal self-resolving acute inflammation and established resolution indices, we provide the first evidence of the pharmacological efficacy of RvD1 administered orally. At doses as low as 1-100 ng/mouse, RvD1 reduced total leukocyte infiltration by ϳ40 -60% and PMN accumulation by ϳ50% at 3 h peritonitis and sharply modified select resolution indices, reducing ⌿ max and R i ( Fig. 2 and Table 2 ). For comparison in this model, dexamethasone or ibuprofen produce a 50 -60% inhibition of PMN infiltration on oral administration of 500 g/kg and 100 mg/kg, respectively (53) . When administered with a therapeutic-like regimen at the peak of acute peritonitis, RvD1 significantly dampened total leukocytes and PMN accumulation, shortened the onset of resolution, increased the relative abundance of M⌽s in exudates, and rescued the outcome of exacerbated, prolonged inflammation, driving it toward resolution. In addition, RvD1 gave time-and cell-specific regulation of leukocyte infiltration during peritonitis. For instance, it lowered eosinophils and lymphocytes at early time points, while increasing M⌽s in the resolution time interval and enhancing their function. These findings indicate that RvD1, unlike immunosuppressant drugs (e.g., steroids, azathioprine, FK506; ref. 54) does not act as a panleukocyte blocker. Together with the observation that RvD1 plasma levels rapidly increased after oral delivery ( Fig. 1) , these results indicate that native RvD1 resists degradation in the acidic gastric milieu and is rapidly absorbed, likely by passive diffusion across gastric mucosa membranes as nonionized carboxylic acid or by carrier-mediated transport (49) , to reach therapeutic levels in plasma and exert potent bioactions. Interestingly, potency and effective dose range of oral RvD1 are comparable to those reported for intravenously or topically delivered RvD1 (23, 30) or for oral native LXs and LX-stable analogs (15, 16) . Therefore, the efficacy of RvD1 as potent immunoresolvent on oral delivery is of considerable interest in clinical immunopharmacology, given the lower invasiveness and the better patient compliance of the oral route compared to parenteral administration. These results also encourage ad hoc preclinical and clinical trials to define PK and pharmacodynamics of RvD1 on oral administration. They also support the therapeutic applicability of RvD1 as a dual-acting drug that simultaneously dampens excessive PMN influx and stimulates resolution activities of M⌽s, which is a relevant clinical issue, since a number of anti-inflammatory molecules are toxic to resolution (3, 11) . Oral administration of RvD1 produced a transient increase in its plasma concentrations. The calculated AUC 0-last was ϳ4.5 ng/h/ml, while basal plasma levels (ϳ0.2 ng/ml or ϳ500 pM; Fig. 1 ), were ϳ10-fold higher than those reported in human plasma (i.e., ϳ45 pM) (25) . Notably, at these concentrations, RvD1 potently dampens PMN recruitment to vascular endothelial cells (33) , as well as endothelial transmigration (23) both in mice and humans. Therefore, it is likely that RvD1 in peripheral blood can exert regulatory func- tions on leukocyte diapedesis on oral administration. In addition, Weiss et al. (55) recently identified RvD1 in human breast milk, hypothesizing that it may regulate immune functions in the gastrointestinal tract of the newborns. Our present results are consistent with this hypothesis and suggest that RvD1 present in human milk can also act systemically or at distal sites on oral absorption to regulate inflammatory responses. We also showed that RvD1 distributed in an apparent V d ϳ 22 ml, which is much higher than the estimated mouse blood total volume (i.e., 1.1 ml/20 g body weight; ref. 56) , indicating that the distribution of RvD1 is not limited to the vascular compartment, in line with its lipophilic structure. Elimination of RvD1 from plasma followed a first-order kinetics, consistent with a linear, nonsaturable, dose-dependent process common to many drugs (49) . Previous studies have demonstrated that inactivation of RvD1 occurs mainly through oxidation by eicosanoid oxidoreductase, as well as an 11␤-hydroxysteroid dehydrogenase, enzymes highly expressed in liver, lung, fat tissue, and kidneys (22, 23) . Therefore, it is likely that the disappearance of RvD1 from plasma (with T 1/2 ϳ3 h) is the result of metabolic degradation and elimination by these organs.
The role of M⌽s in resolution of inflammation and restoration of homeostasis is widely appreciated (39) , and molecules that promote their tasks are of general interest in immunopharmacology. Here, we show that the down-regulation of enzymes linked to the epigenetic control of mRNA transcription in M⌽s (Figs. 5 and 6) represents key RvD1-induced signaling in these cells. In particular, RvD1 reduced the expression of the histone H3 methylase CARM1 (Fig. 5 ), which plays a pivotal role during M⌽ activation by acting as a coactivator of a number of NF-B-dependent genes (52) . Indeed, siRNA-mediated knockdown of CARM1 reduced up-regulation of ICAM-1 and MIP-2 in M⌽s in response to LPS, while it enhanced their phagocytic activities both in vitro and in vivo, recapitulating RvD1 actions on these cells. Consistent with this, RvD1 significantly lowered the expression of the CARM1-regulated genes CSF3, MIP-2, and ICAM-1, which are characteristics of proinflammatory M1 M⌽s, and increased phagocytosis-mediated clearance of PMN-inflamed peritonea (Fig. 6) , demonstrating the ability to skew M⌽s toward a proresolution phenotype. Interestingly, RvD1 did not change expression levels of COX-2 and IB in resolution-phase M⌽s. Previous studies have shown that RvD1 reduces hypoxia-induced up-regulation of COX-2 in liver tissues (57) and NF-B in LPS-inflamed lungs (58), but it does not alter COX-2 levels in ocular tissues (59) . Therefore, it appears that RvD1 carries selective, tissue-specific regulatory activities on these genes.
RvD1 also down-regulated HDAC5 and HDAC7, which are members of the protein kinase D-dependent class IIa of HDACs involved in tumor growth and proinflammation. For instance, HDAC7 is highly expressed in thioglycollate-elicited murine M1 M⌽s, where it enhances TLR signaling and activates transcription of proinflammatory genes (60) . In addition, HDACs are targets of synthetic inhibitors that carry proresolution activities mediated by AnxA1 via ALX/ FPR2 (61) . Thus, it is likely that RvD1 and AnxA1 converge to the ALX/FPR2 receptor to stimulate proresolution events via the regulation of HDACs. These results support the concept that ALX/FPR2 stands at the crossroad of multiple proresolution pathways. Our recent uncovering of the ALX/FPR2 promoter of human ALX/FPR2 (62) will be helpful for a better understanding of the regulatory pathways of this receptor, as well as the potential crosstalk between HDACs and resolution mechanisms.
RvD1-down-regulated enzymes in resolution-phase M⌽s include RPS6K (Fig. 5) , a Ser/Thr kinase that represses transcription via phosphorylation of histone H2a and H3 in response to inflammatory, mitogenic, or stress stimuli (63) . Interestingly, this kinase is instead activated by RvE1 through ChemR23 receptor (64) to promote phagocytosis in M⌽s. This indicates that RvD1 and E1, although sharing immunoresolvents properties, elicit distinct regulatory pathways in the resolution process (5) . As an example, RvD1 and E1 oppositely regulate interferon-␥, LXA 4 , and IL-5 in airway exudates during the resolution of allergic inflammation (ref. 27 ; reviewed in ref. 5) .
Taken together, our present results unveil potent immunoresolving actions of RvD1 after oral administration, which are of translational and clinical relevance. They also reveal that RvD1 acts on epigenetic control mechanisms of gene expression to enhance M⌽-dependent resolution of acute inflammation. This evidence establishes novel immunoresolving mechanisms of action of RvD1 that may be therapeutically exploited for treating inflammation-related human diseases. 
